ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lutetium-177

Also written as “[177Lu]Lu-NeoB”, “[177Lu]Lu-PSMA-617” and “Lutetium[177Lu] Oxodotreotide Injection”.

In Novartis’s pipeline, Radioligand therapy target HER2. Its studies are mostly in Prostatic Neoplasms · Breast Neoplasms · Neuroendocrine Tumors · Glioblastoma · Carcinoma, Non-Small-Cell Lung, led by 11 companies.

Drug pageLutetium-177: every studyMany companies study it; this page follows only the 24 they lead. All 41 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 16, 202024 company-led studies, 19 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only107 open or runningphase 2since Dec 16, 2020Dec 16, 2020Dec 30, 2026phase 1 · NCT05870579
Sinotau Pharmaceutical Groupits history only32 open or runningphase 3since Jul 5, 2022Jul 5, 2022Jun 1, 2027phase 3 · NCT06398444
Braccoits history only21 open or runningphase 2since May 20, 2022May 20, 2022none ahead
Sichuan Biokin Pharmaceuticalits history only22 open or runningphase 1since Nov 14, 2025Nov 14, 2025Dec 2027phase 1 · NCT07232407
Affibodyits history only11 open or runningphase 1since Jun 23, 2025Jun 23, 2025Jun 1, 2027phase 1 · NCT07081555
Alpha-9 Oncology USAits history only11 open or runningphase 1since Jun 9, 2026Jun 9, 2026Dec 2028phase 1 · NCT07661641
Cellbion11 open or runningphase 1since Nov 14, 2025Nov 14, 2025Apr 2029phase 1 · NCT07244393
FutureChemits history only11 open or runningphase 2since Jun 10, 2022Jun 10, 2022none ahead
Jiangsu HengRui Medicineits history only11 open or runningphase 3since May 22, 2023May 22, 2023Dec 2026phase 3 · NCT05884255
Philogenits history only11 open or runningphase 1since Oct 10, 2024Oct 10, 2024May 31, 2028phase 1 · NCT06640413

Also a collaborator on its studies: Merck, PSI CRO, Baili-Bio (Chengdu) Pharmaceutical and Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cellbion only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First study: phase 1 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)First studyNCT07244393 · 30 planned · South Korea

Ahead

  1. Apr 2029Primary completion: phase 1 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07244393

TargetBeta

“Radioligand therapy target HER2”the company's pipeline, read by Claude · source
“Radioligand therapy target FAP”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Gallium-68Philogenphase 317

Studies

The one study Cellbion leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07244393Metastatic Castration-resistant Prostate Cancer (mCRPC) · South Korea1RecruitingApr 202930

How it is read

Names in the registry

  • “[177Lu]Lu-NeoB”, 4 entries
  • “[177Lu]Lu-PSMA-617”, 3 entries
  • “Lutetium[177Lu] Oxodotreotide Injection”, 2 entries
  • “Lutetium [177Lu] BL-ARC001”, 2 entries
  • “[177Lu]Lu-ABY-271”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.